英文文獻(xiàn)匯報(bào)_第1頁
英文文獻(xiàn)匯報(bào)_第2頁
英文文獻(xiàn)匯報(bào)_第3頁
英文文獻(xiàn)匯報(bào)_第4頁
英文文獻(xiàn)匯報(bào)_第5頁
已閱讀5頁,還剩10頁未讀, 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡介

IF=2.2181.IntroductionMerozoitesurfaceprotein-1ofmalariaparasites,presentonthesurfaceofmerozoiteandplayingakeyroleintheinvasionprocess,isoneoftheleadingvaccinetargetsforbothP.falciparumandP.vivaxmalaria.MSP-1occursasa200kDaprecursorandundergoesstep-wiseproteolyticprocessingresultinginaglycosyl-phosphatidylinositol-anchored42kDaproteinfragment(MSP-142)onthesurfaceoffreemerozoite.AlargenumberofstudieshaveshowntheprotectivepotentialofMSP-1fragments(42and19kDa)ofP.falci-parumandP.yoelii.DNAvaccineshaveemergedasapromisingapproachforavarietyofinfectiousagentsincludingmalariaparasites.DNAbasedvaccinesareparticularlyimportantfordevelopingmultistage/multiantigenvaccinesforcomplexparasiteslikemalariatherebyinducingspecificandprotectiveimmunityagainstdifferentlifecyclestages(pre-erythrocytic,erythrocyticandsexualstages)ofmalaria.TheadvantagesofDNAvaccinesaretheeaseoftheirproductionandtheirabilitytoinduceresponseswithoutanyexogenousadjuvant,whichisanabsoluterequirementforproteinbasedvaccineformulations.DNAvaccineshavebeenshowntoinducestronghumoralandcellularresponsestomalarialantigensinimmunized.However,clinicaltrialsofthesecandidatevaccineswhenusedaloneorinrepeatedhomologousboostingregimenshavebeendisappointing,withshortlivedlowlevelsofinducedspecificT-cellsresponses.Sequentialimmunizationwithdifferentplasmids/vectorsknownasheterologousprime-boostingappearstobeabetterapproachandhasbeenshowntoinduceenhancedandpersistentlevelsofantibodyandcellmediatedimmuneresponsesagainstmalaria.Inheterologousprime-boostingstrategytheprimingwasdonewithDNAfollowedbytheboosterimmunizationwitharecombinantprotein,arecombinantviralvaccine,orexposuretotheliveorganism.InthepresentstudywehaveevaluatedtheimmunogenicityofaDNAvaccineencodingMSP-142ofP.vivaxusingprime-boostingstrategyinBALB/cmice.WehavealsocomparedtheimmunogenicityofPvMSP-142recombinantproteininBALB/cmice.2.MaterialsandmethodsDNAvaccineconstructsencodingP.vivaxMSP-142InvitrotransfectionofmammaliancellswithP.vivaxMSP-142–pcDNA3.1plasmidMonoclonalantibodiesagainstP.vivaxMSP-142LocalizationofP.vivaxMSP-142byindirectimmunofluorescenceSDS–PAGEandimmunoblottingPurificationofrecombinantP.vivaxMSP-142expressedinE.coliPurificationofplasmidforimmunizationImmunizationstudiesinmiceEnzymelinkedimmunosorbentassayDeterminationofIgGsubclassesCellproliferationassayDetectionofcytokinesIFN-γ,IL-2andIL-12byELISA3.Results

3.1.ConstructionofaP.vivaxmerozoitesurfaceprotein-142-pcDNA3.1plasmidDNAvaccineanditsinvitroexpressioninCOS1cells3.2.AntibodyresponsesinimmunemiceagainstP.vivaxmerozoitesurfaceprotein-142-pcDNA3.1DNAvaccineconstructandrecombinantPvMSP-142protein3.3.MeasurementofP.vivaxmerozoitesurfaceprotein-142specificIgGisotypesinimmunemicesera3.4.InvitroTcellresponsesagainstP.vivaxmerozoitesurfaceprotein-1423.5.InvitrocytokinesproductionagainstP.vivaxmerozoitesurfaceprotein-1424.DiscussionsInthepresentstudy,wehavepreparedaplasmidDNAconstructencodingP.vivaxPvMSP-142antigen.TheexpressionofPvMSP-142proteinwascheckedbyinvitrotransfectionofCOS-1mammaliancellswithPvMSP-142-pcDNA3.1plasmidDNAconstruct.ImmunogenicityofPvMSP-142DNAvaccineconstructwasinvestigatedbyprimingtheBALB/cmiceeitherwithPvMSP-142plasmidDNAorwithrecombinantPvMSP-142proteinandboostingwithrecombinantPvMSP-142protein.InthepresentstudywehaveconductedDNAvaccinationforP.vivaxMSP-142andcomparedtheimmunogenicityofDNAvaccineconstructwithcorrespondingproteinvaccinationinBALB/cmice.ImmunizationofmicewithrecombinantPvMSP-142resultedintheinductionofhightitresofanti-rPvMSP-142antibodiesthanthatofDNAimmunization.However,theantibodytitresobservedinPvMSP-142plasmidDNAimmunizedmiceweresignificantlyhigherthanthemiceinthecontrolgroup(vectorimmunized).DNAvaccineplasmidsencodingmerozoitesurfaceprotein-1frommurinemalariahasbeenshowntoprovideprotectionagainstmalariainfection.Theimportanceofheterologousprime-booststrategyinmalariainfectionhasbeendemonstratedbyanumberofstudies.Inthepresentstudy,primingwithP.vivaxMSP-142plasmidDNAandboostingwithrecombinantPvMSP-142proteinexhibitedasignificantincreaseintheantibodyresponsesinDNA/ProteingroupcomparedtoDNA/DNAgroupasitwasevidentoncomparingthe1ODtitreaswellasendpointtitrevaluesofdifferentimmunizedgroups.TheseresultssuggestthattheprimingwithplasmidDNAandboostingwithrecombinantproteinisessentialfortheenhancementofimmuneresponses.However,theantibodytitresinProtein/ProteingroupweresignificantlyhigherthanDNA/Proteingroup.ThismaybeattributedtotheuseofFCA/IFAforproteinimmunizationwhichresultedinhighlevelsofantibodyinProtein/Proteingroup.Previousstudieshaveshownthatcellmediatedimmuneresponses,inadditiontoantibodyresponses,arerequiredforprotectionagainstmalaria.PresentstudyonmeasuringTcellresponsesinmiceafterDNAimmunizationandproteinboostingexhibitedthatTcellproliferationwassignificantlyenhancedinDNA/ProteinandProtein/Proteingroups.Elevatedlevelsofcytokines(IL-2,IL-12,andIFN-γ)andhightitresofantigenspecificIgGisotypes(IgG1>IgG2b>IgG2a)indicatedthatbothTh1andTh2subsetsofThelpercellsmaybeproducedduringimmunizationofmiceinthepresentstudy.Thistypeofresponses,i.e.,theactivationofbothTh1andTh2cells,isconsideredidealforablood-stagevaccine.OurfindingsonDNAprimeandproteinboostinghavealsoindicatedthatamongtheDNAimmunizedgroups,primingwithDNAandboostingwithproteinclearlyelevatedthelevelsofallthecytokinesinDNA/ProteingroupsuggestingthatDNAcanprimethemicebutitselfisnotsufficientenoughtoenhancetheimmuneresponses.5.ConclusionsInthepresentstudy,wehavecloned42kDafragmentofP.vivaxmerozoitesurfaceprotein-1(PvMSP-142)ineukaryoticexpressionvectorpcDNA3.1.WecheckedtheinvitroexpressionofPvMSP-142-pcDNA3.1inCOS-1cellline.Indirectfluorescentassayandwesternblottingconfirmed

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

最新文檔

評(píng)論

0/150

提交評(píng)論